Intra-Trigonal Injection of Botulinum Toxin a in Patients With Bladder Pain Syndrome - Results at 9-Months Follow-Up

Pinto, Rui; Silva, André; Lopes, Teresa da Silva; Silva, João Figueira; Silva, Carlos M.; Cruz, Francisco; Dinis, P.

doi:10.1016/s0022-5347(09)60068-9

Cited by 6 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Painful bladder syndrome is a clinical syndrome characterized by pain with supra-pubian localization caused by bladder filling associated with increased urinary frequency both day and night in the absence of proven urinary infection. There is currently no standard treatment [ 93 ], but there are studies in the literature that confirm the efficiency of BoNT-A in the management of interstitial cystitis, which has an antinociceptive effect on the visceral afferent nervous fibers [ 94 ].…”

Section: Review Of the Literature Regarding The Gynecologic Indicamentioning

confidence: 99%

Therapeutic Approaches of Botulinum Toxin in Gynecology

Moga

Dimienescu

Bălan

et al. 2018

Toxins

View full text Add to dashboard Cite

Botulinum toxins (BoNTs) are produced by several anaerobic species of the genus Clostridium and, although they were originally considered lethal toxins, today they find their usefulness in the treatment of a wide range of pathologies in various medical specialties. Botulinum neurotoxin has been identified in seven different isoforms (BoNT-A, BoNT-B, BoNT-C, BoNT-D, BoNT-E, BoNT-F, and BoNT-G). Neurotoxigenic Clostridia can produce more than 40 different BoNT subtypes and, recently, a new BoNT serotype (BoNT-X) has been reported in some studies. BoNT-X has not been shown to actually be an active neurotoxin despite its catalytically active LC, so it should be described as a putative eighth serotype. The mechanism of action of the serotypes is similar: they inhibit the release of acetylcholine from the nerve endings but their therapeutically potency varies. Botulinum toxin type A (BoNT-A) is the most studied serotype for therapeutic purposes. Regarding the gynecological pathology, a series of studies based on the efficiency of its use in the treatment of refractory myofascial pelvic pain, vaginism, dyspareunia, vulvodynia and overactive bladder or urinary incontinence have been reported. The current study is a review of the literature regarding the efficiency of BoNT-A in the gynecological pathology and on the long and short-term effects of its administration.

show abstract

Section: Review Of the Literature Regarding The Gynecologic Indicamentioning

confidence: 99%

Therapeutic Approaches of Botulinum Toxin in Gynecology

Moga

Dimienescu

Bălan

et al. 2018

Toxins

View full text Add to dashboard Cite

show abstract

“…Botulinum toxin type A injections for bladder pain syndrome/interstitial cystitis Small, recent studies suggest that BoNT/A could represent an alternative choice to patients with BPS/IC [15,63,64]. However, there are not any placebo-controlled studies available as yet in BPS/IC patients.…”

Section: Botulinum Toxin Type a Injections For Refractory Neurogenic mentioning

confidence: 99%

“…Therefore, BoNT/A indication in BPS/IC should be understood as completely investigational and should not be offered outside a clinical trial. To diminish the risk of urinary retention, the toxin should be injected in small doses, either into the submucosa [15,63] or in the bladder trigone [64].…”

Section: Botulinum Toxin Type a Injections For Refractory Neurogenic mentioning

confidence: 99%

Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it?

Martins-Silva

Cruz

2009

Current Opinion in Urology

View full text Add to dashboard Cite

Although still waiting for approval, BoNT/A detrusor injections can be safely offered to well informed patients with refractory neurogenic detrusor overactivity, as an alternative to more invasive therapies, such as bladder augmentation. Ongoing studies are expected to come up with the necessary information for definitive approval of BoNT/A in neurogenic detrusor overactivity patients. Regarding other possible applications such as idiopathic detrusor overactivity, benign prostatic enlargement and bladder pain syndrome/interstitial cystitis, its use should still be restricted to research centres in well designed clinical trials.

show abstract

“…Preliminary evidence suggested that Botulinum toxin A (BTXA) may be effective for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS) when injected into the bladder wall (1)(2)(3)(4)(5).…”

Section: Introductionmentioning

confidence: 99%